Earnings ·
Merck reports Q3 EPS of $2.04, raises full-year sales outlook to $66.8B-$67.3B
MRKMerck & Co., Inc.
Merck & Co., Inc. reported third-quarter 2026 GAAP earnings per share of $2.04 and non-GAAP EPS of $2.49, both including a one-time charge of $0.12 per share related to a global license agreement with SciBrunch. Worldwide sales reached $18.1 billion, reflecting 5% growth driven by KEYTRUDA ($8.6 billion) and WINREVAIR ($694 million). The company narrowed and raised its full-year 2026 sales outlook to between $66.8 billion and $67.3 billion, while raising the expected non-GAAP EPS range to $2.77-$2.82. Merck operates as a research-intensive biopharmaceutical company developing medicines and vaccines.